Education
About Us
Working with TipRanks
Follow Us
Integrum AB Class B (DE:6Y1)
FRANKFURT:6Y1
6Y1 Stock Chart & Stats
€0.94
-€0.06(-3.43%)
At close: 4:00 PM EST
€0.94
-€0.06(-3.43%)
Day’s Range― - ―
52-Week Range€0.68 - €3.86
Previous CloseN/A
Volume0.00
Average Volume (3M)8.00
Market Cap
€21.32M
Enterprise Value€177.32M
Total Cash (Recent Filing)€7.77M
Total Debt (Recent Filing)€4.02M
Price to Earnings (P/E)―
Beta0.04
Next Earnings
Mar 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding26,027,910
10 Day Avg. Volume6
30 Day Avg. Volume8
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.64
Price to Sales (P/S)3.20
P/FCF Ratio-5.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Niche Specialized Business ModelIntegrum's focused OPRA osseointegration system targets a high-barrier, specialized medical niche with durable demand from amputee rehabilitation centers. This vertical focus supports deep clinical expertise, long-term customer relationships, recurring component and service sales, and differentiation that is hard for generalist competitors to replicate.
Robust Revenue GrowthSustained, material revenue growth (58.1% TTM; ~62% revenue growth metric) indicates accelerating adoption of the OPRA system and stronger commercial execution. Over 2-6 months this supports scaling economics, improved negotiating leverage with clinics, and a larger installed base that can drive recurring parts and service revenue.
Conservative Balance Sheet With Low LeverageLow leverage and a healthy equity ratio provide financial flexibility to fund clinical rollouts, regulatory work, and R&D without heavy refinancing pressure. This durable capital structure reduces bankruptcy risk and preserves optionality for strategic investments or partnerships over the medium term.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating cash flow, despite slight free cash flow improvement, signals that core operations do not yet generate sustainable cash. For a small med‑tech company this can force reliance on external funding, constrain clinic expansion and training programs, and limit the pace of commercialization.
Unprofitable Operations / Weak MarginsNegative EBIT and net margins despite healthy gross margin point to structurally high operating or commercial costs. If operating cost intensity persists, scaling revenue may not translate to sustainable profitability without structural cost reductions, pricing power, or higher volumes to absorb fixed costs.
Limited Scale And Operational InefficienciesA small organizational footprint (36 employees) combined with reported operational inefficiencies suggests limited capacity to execute broad clinical rollouts and global commercialization. This scale constraint can slow adoption, increase per-unit costs, and prolong the timeline to achieve efficient, profitable operations.
Integrum AB Class B News
6Y1 FAQ
What was Integrum AB Class B’s price range in the past 12 months?
Integrum AB Class B lowest stock price was €0.68 and its highest was €3.86 in the past 12 months.
What is Integrum AB Class B’s market cap?
Integrum AB Class B’s market cap is €21.32M.
When is Integrum AB Class B’s upcoming earnings report date?
Integrum AB Class B’s upcoming earnings report date is Mar 02, 2026 which is in 5 days.
How were Integrum AB Class B’s earnings last quarter?
Integrum AB Class B released its earnings results on Nov 21, 2025. The company reported -€0.032 earnings per share for the quarter, missing the consensus estimate of -€0.002 by -€0.03.
Is Integrum AB Class B overvalued?
According to Wall Street analysts Integrum AB Class B’s price is currently Overvalued.
Does Integrum AB Class B pay dividends?
Integrum AB Class B does not currently pay dividends.
What is Integrum AB Class B’s EPS estimate?
Integrum AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Integrum AB Class B have?
Integrum AB Class B has 26,027,910 shares outstanding.
What happened to Integrum AB Class B’s price movement after its last earnings report?
Integrum AB Class B reported an EPS of -€0.032 in its last earnings report, missing expectations of -€0.002. Following the earnings report the stock price went down -0.135%.
Which hedge fund is a major shareholder of Integrum AB Class B?
Currently, no hedge funds are holding shares in DE:6Y1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Integrum AB Class B
Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoiding bone fractures from accidental loads. The company also provides Neuromotus, a technology that is used for therapy to reduce phantom limb pain after an amputation. It sells its implant systems to hospitals, clinics, and orthopedists worldwide. The company was founded in 1962 and is headquartered in Mölndal, Sweden.